November 16, 2020 -- Abpro has published preclinical data in a Nature Communications article demonstrating the prophylactic and therapeutic production of neutralizing antibodies by its candidate, ABP 300, a monoclonal antibody (mAb) therapy against COVID-19.
ABP 300 works by binding the receptor-binding domain of the SARS-CoV-2 spike protein to block viral interaction with angiotensin-converting enzyme 2 (ACE2) receptors.
In the study, a single dose of ABP 300 blocked infection of SARS-CoV-2 in rhesus monkeys and cleared SARS-CoV-2 in three days when given as a therapeutic. The company demonstrated the protective effect of ABP 300 against lung lesions caused by SARS-CoV-2 in monkeys in both capacities. ABP 300 has also been shown to effectively neutralize SARS-CoV-2 pseudovirus and authentic live virus.
The data from preclinical nonhuman primate studies will support further development of the company's monoclonal antibodies in human subjects. ABP 300 recently completed a phase I dose escalation study in human subjects.